Status:

COMPLETED

Effects of Growth Hormone on the Nitric Oxide Pathway

Lead Sponsor:

Hannover Medical School

Collaborating Sponsors:

Pharmacia

Conditions:

Cardiovascular Disease

Eligibility:

MALE

50+ years

Phase:

PHASE1

Brief Summary

The purpose of the study is to determine whether the treatment with growth hormone has an influence on the nitric oxide pathway in healthy males.

Detailed Description

Nitric oxide (NO) is a potent endogenous vasodilator and has shown to inhibit key processes of atherosclerosis like monocyte adhesion, platelet aggregation, and vascular smooth muscle cell proliferati...

Eligibility Criteria

Inclusion

  • Healthy male subjects without recent severe diseases
  • Age 50 yrs or older
  • Body mass index at or below 30 kg/m2
  • Insulin-like growth factor-1 level below 200 ng/ml
  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial
  • Subjects that are willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

Exclusion

  • History of any severe hepatic, renal, cardiac, endocrine, metabolic, or malignant diseases
  • Requirement for medical drug treatment
  • Growth hormone treatment during the last 12 months
  • Drug dependence, alcohol or nicotine abuse
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for entry into this study.

Key Trial Info

Start Date :

May 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2005

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT00470002

Start Date

May 1 2004

End Date

January 1 2005

Last Update

May 7 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institute of Clinical Pharmacology, Hannover Medical School

Hanover, Lower Saxony, Germany, 30623